 |
|
Drug for rheumatism possible boon to heart patients
October 08, 2004Atheromatosis, which lies behind heart attacks, stroke, and other cardiovascular problems, has a major impact on public health. So does chronic rheumatoid arthritis. These two diseases are completely different from each other, but they do have one common denominator: inflammation. Researchers at Lund University in Sweden can now show that it might also be possible to treat them with the same drug.
Chronic rheumatoid arthritis (RA) is a result of inflammation of the joints. Inflammation is actually the body's way of dealing with infections caused by bacteria, but in rheumatoid arthritis the immune system overreacts, attacking the body's own tissues.
Inflammation is also involved in atherosclerosis (also called hardening of the arteries). When fat is stored in blood vessels and becomes rancid, the body tries to rid itself of the fat by calling in so-called inflammatory cells, white corpuscles. But the reaction is often too powerful, so the inflammatory cells start to break down the walls of the vessels in the same way they break down joint cartilage and bone in rheumatoid arthritis.
A central role in inflammation in rheumatoid arthritis is played by a signal molecule called TNF-alpha. Heart scientist Stefan Jovinge can now show that TNF-alpha is also involved in atheromatosis/atherosclerosis. His research team first developed a special breed of mice that was prone to develop this disease, whereupon they knocked out the gene for TNF-alpha and found that the mice developed less atheromatosis/atherosclerosis.
The same result was achieved by giving these atheromatosis-conditioned mice a drug that impedes the effect of TNF in the body. The findings have recently been published in the journal "Arteriosclerosis, Thrombosis and Vascular Biology".
At the same time, working with rheumatology units in southern Sweden, rheumatologist Lennart Jacobsson at Malmö University Hospital has studied the use of new TNF-inhibiting drugs on patients with chronic rheumatic arthritis. In some 1,500 patients, the symptoms of the joint disorder were substantially alleviated, and at the same time the risk of coronary disease-which otherwise is higher among these patients-fell to nearly half.
The two research teams are now carrying on their collaboration, which is unique in many ways and has attracted much international attention. Already roughly a fifth of all patients with rheumatoid arthritis in Malmö are treated with a TNF inhibitor, and Stefan Jovinge hopes to be able to test the medicine on special groups of heart patients in about a year. If the theories hold true, in the future the drug may be used for a large proportion of heart patients.
Vetenskapsrådet (The Swedish Research Council)
A central role in inflammation in rheumatoid arthritis is played by a signal molecule called TNF-alpha. Heart scientist Stefan Jovinge can now show that TNF-alpha is also involved in atheromatosis/atherosclerosis. His research team first developed a special breed of mice that was prone to develop this disease, whereupon they knocked out the gene for TNF-alpha and found that the mice developed less atheromatosis/atherosclerosis.
The same result was achieved by giving these atheromatosis-conditioned mice a drug that impedes the effect of TNF in the body. The findings have recently been published in the journal "Arteriosclerosis, Thrombosis and Vascular Biology".
At the same time, working with rheumatology units in southern Sweden, rheumatologist Lennart Jacobsson at Malmö University Hospital has studied the use of new TNF-inhibiting drugs on patients with chronic rheumatic arthritis. In some 1,500 patients, the symptoms of the joint disorder were substantially alleviated, and at the same time the risk of coronary disease-which otherwise is higher among these patients-fell to nearly half.
The two research teams are now carrying on their collaboration, which is unique in many ways and has attracted much international attention. Already roughly a fifth of all patients with rheumatoid arthritis in Malmö are treated with a TNF inhibitor, and Stefan Jovinge hopes to be able to test the medicine on special groups of heart patients in about a year. If the theories hold true, in the future the drug may be used for a large proportion of heart patients.
Vetenskapsrådet (The Swedish Research Council)
Arthritis Current Events and Arthritis News RSSMultiple health concerns surface as winter, vitamin D deficiences arrive
A string of recent discoveries about the multiple health benefits of vitamin D has renewed interest in this multi-purpose nutrient, increased awareness of the huge numbers of people who are deficient in it, spurred research and even led to an appreciation of it as "nature's antibiotic."
Can EP4 agonist alleviate gastric lesions?
Over 300 million patients use non-steroidal anti-inflammatory drugs (NSAIDs) in the world to treat pain, arthritis, fever and other diseases. Nearly 30% of the users suffer from gastric lesions and bleeding.
Thoughtful words help couples stay fighting fit
Couples who bring thoughtful words to a fight release lower amounts of stress-related proteins, suggesting that rational communication between partners can ease the impact of marital conflict on the immune system.
Penn Study Provides First Clear Idea of How Rare Bone Disease Progresses
An international team of scientists, led by researchers at the University of Pennsylvania School of Medicine, is taking the first step in developing a treatment for a rare genetic disorder called fibrodysplasia ossificans progressiva (FOP), in which the body's skeletal muscles and soft connective tissue turns to bone, immobilizing patients over a lifetime with a second skeleton.
Aileron collaborates study in Nature: Stapled peptides inhibit Notch1 transcription factor
This research validates the potential for Stapled Peptides to modulate key intracellular biological targets, such as transcription factors, that have not been addressable with current small molecule or biologic drug modalities.
Researchers find new way to attack inflammation in Graves' eye disease
A small group of patients with severe Graves' eye disease experienced rapid improvement of their symptoms - and improved vision - following treatment with the drug rituximab.
Common Pain Relievers May Dilute Power of Flu Shots
With flu vaccination season in full swing, research from the University of Rochester Medical Center cautions that use of many common pain killers - Advil, Tylenol, aspirin - at the time of injection may blunt the effect of the shot and have a negative effect on the immune system.
Mending meniscals in children, improving diagnosis and recovery
The meniscus is a rubber-like, crescent moon-shaped cartilage cushion that sits between the leg and thigh bone. Each knee has two menisci: one on the inside of the knee joint and one on the outside.
Study finds link between childhood physical abuse and arthritis
Adults who had experienced physical abuse as children have 56 per cent higher odds of osteoarthritis compared to those who have not been abused, according to a new study by University of Toronto researchers.
Pain thresholds linked to inflammation and sleep problems in arthritis patients
Despite recent advances in anti-inflammatory therapy, many rheumatoid arthritis (RA) patients continue to suffer from pain.
More Arthritis Current Events and Arthritis News Articles
| © 2009 BrightSurf.com |